Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab A/S    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 11/24 10:55:00 am
2203 DKK   -3.21%
11:09aGENMAB A/S : Announces Enapotamab Vedotin Update
AQ
11:09aGENMAB A/S : Announces Enapotamab Vedotin Update
AQ
11:09aGenmab Announces Enapotamab Vedotin Update
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:

- royalties (58.8%);

- income from research and development (34.8%);

- other (6.4%): primarily income from partnership agreement.

At the end of 2019, the group had a portfolio of 18 products in clinical development phase and 20 in preclinical development phase.

Denmark accounts for all net sales.

Number of employees : 548 people.
Sales per Business
20182019Delta
DKK (in Million)%DKK (in Million)%
Human Antibody Therapeutics3,025100%5,366100% +77.38%
Sales per region
20182019Delta
DKK (in Million)%DKK (in Million)%
Denmark3,025100%5,366100% +77.38%
Managers
NameAgeSinceTitle
Jan G. J. van de Winkel582010President & Chief Executive Officer
Deirdre Connelly582020Chairman
Anthony Mancini-2020Chief Operating Officer & Executive Vice President
Anthony Pagano412020Chief Financial Officer & Executive Vice President
Michael K. Bauer552010SVP, Head-Operations, Research & Development
Anders Gersel Pedersen, Dr.68-Non-Independent Director
Pernille Lyngvold Erenbjerg522020Deputy Chairman
Paolo Augusto Paoletti, Dr.682015Independent Director
Peter Storm Kristensen452016Non-Independent Director
Rolf K. Hoffmann60-Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 65,545,748 62,371,184 95.2% 135,518 0.2% 95.2%
Shareholders
NameEquities%
Baillie Gifford & Co. 3,704,452 5.66%
Artisan Partners LP 3,081,731 4.71%
Wellington Management Co. LLP 2,152,223 3.29%
The Vanguard Group, Inc. 1,785,106 2.73%
Norges Bank Investment Management 1,311,352 2.00%
BlackRock Fund Advisors 975,958 1.49%
EdgePoint Investment Group, Inc. 865,782 1.32%
BlackRock Advisors LLC 859,306 1.31%
GQG Partners LLC 809,720 1.24%
Capital Research & Management Co. (World Investors) 680,696 1.04%
Holdings
NameEquities%Valuation
Genmab A/S (GMAB) 163,9210.25%54,602,290 USD
Markets and indexes
-
- Main Market Large
- OMXC 20 / NASDAQ OMX Nordic 120, OMX Nordic 40, STOXX Europe 600
Stock Exchange Codes
- Bloomberg Code :  GEN:DC
- Reuters Code :  GEN.CO
- Datastream Code :  
Company contact information
Genmab A/S
Kalvebod Brygge 43
DK-1560 Copenhagen V


Phone : +45 70 20 27 28
Fax : +45 70 20 27 29
web site : http://www.genmab.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
GENMAB A/S61.40%23 640
GILEAD SCIENCES, INC.-7.83%75 074
VERTEX PHARMACEUTICALS-0.49%56 654
REGENERON PHARMACEUTICALS39.45%55 264
WUXI APPTEC CO., LTD.63.37%39 757
BIONTECH SE214.34%25 644
BEIGENE, LTD.65.17%24 956
ARGENX SE56.96%12 606
MYOKARDIA, INC.208.58%11 993
HUALAN BIOLOGICAL ENGINEERING INC.57.18%11 785
MIRATI THERAPEUTICS, INC.74.61%11 313
SAREPTA THERAPEUTICS, INC.4.22%10 613
NEUROCRINE BIOSCIENCES, INC.-17.20%8 747
ASCENDIS PHARMA A/S13.92%8 465
ULTRAGENYX PHARMACEUTICAL INC.168.53%7 587
DENALI THERAPEUTICS INC.257.23%7 463
ARROWHEAD PHARMACEUTICALS, INC.7.52%6 976
ACCELERON PHARMA INC.114.18%6 842
BIOCON LIMITED43.09%6 707
KODIAK SCIENCES INC.74.45%6 328
PEPTIDREAM INC.-14.29%5 774